Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN SODIUM versus ROCEPHIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN SODIUM versus ROCEPHIN.
CEFAZOLIN SODIUM vs ROCEPHIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP1a, PBP1b, PBP2a, PBP2b, PBP2x, PBP3, and PBP4, thereby preventing cross-linking of peptidoglycan chains. This leads to cell lysis and death.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with peptidoglycan cross-linking and leading to cell lysis.
1-2 g IV/IM every 8 hours; maximum 12 g/day for severe infections.
1-2 g IV or IM every 24 hours; maximum 4 g/day for serious infections.
None Documented
None Documented
Approximately 1.8 hours (range 1.2-2.2 h) in normal renal function; prolonged in renal impairment (up to 30-40 h in ESRD)
Terminal half-life ~6-8 hours in adults with normal renal function; prolonged to 12-24 hours in neonates and elderly.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); minimal biliary (1-2%); fecal (<1%)
Renal (33-67%) and biliary (40-50%); primarily excreted unchanged. Dual elimination: ~50% renal, ~50% biliary/fecal.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic